# Genentech Pays $45M Upfront for DualityBio ADCs Targeting Resistant Cancers

Genentech, a Roche subsidiary, has entered a licensing agreement with DualityBio for rights to antibody-drug conjugates (ADCs) designed for patients whose cancers have progressed after prior ADC treatment. The deal includes a $45 million upfront payment and could exceed $1 billion in total milestone payments.

The ADCs are intended to address the growing population of patients who become resistant to existing ADC therapies. Genentech will obtain rights to develop and commercialize the candidates.

**Context**

ADCs are a class of cancer drugs that deliver a toxic payload directly to tumor cells via an antibody. They have become a major focus in oncology, with several approvals in recent years. However, resistance to ADCs is an emerging challenge, as tumors can adapt and stop responding. This deal highlights the biotech industry’s effort to develop next-generation ADCs that can overcome that resistance, an area of active research in precision medicine and drug development.

Source: [original report](https://www.fiercebiotech.com/biotech/genentech-doubles-down-adc-resistant-cancers-1b-dualitybio-pact)